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Abstract
Background: The expression of chemokine receptors CCR7 has been studied in relation to tumor dissemination
and poor prognosis in a limited number of cancers. No such studies have been done on CCR7 expression in non-
Hodgkin’s lymphoma (T-NHL). Our aim in this paper is to investigate the association between CCR7 expression and
progression and prognosis of T-NHL.
Methods: 1) Analysis of clinical data: The specimens were obtained from 41 patients with T-NHL and 19 patients
with lymphoid hyperplasia. Their corresponding clinicopathologic data were also collected. The expression levels of
CCR7, MMP-2, and MMP-9 were examined by immunohistochemical staining. 2) Human T-NHL cell lines Hut 78
(cutaneous T-cell lymphoma) and Jurkat (adult T-cell leukemia/lymphoma) were cultured. The invasiveness of the
two cell lines were measured with a Transwell invasion assay, and then used to study the effects of chemokine
receptors on T-NHL invasion and the underlying molecular mechanism. The transcript and expression of CCR7
were evaluated using RT-PCR and western blotting.
Results: 1) The higher CCR7 and MMP-9 expression ratios were significantly associated with multiple lesions and
higher stage III/IV. Moreover, a positive correlation was observed between CCR7 and MMP-9 expression. 2) The Hut
78 cell line was more invasive than the Jurkat cells in the Transwell invasion assay. The transcript and expression
levels of CCR7 were significantly higher in Hut78 than that of Jurkat cell line. The T-NHL cell lines were co-cultured
with chemokine CCL21 which increased the invasiveness of T-NHL cell. The positive association between CCL21
concentration and invasiveness was found. 3) The stronger transcript and expression of PI3K, Akt and p- Akt were
also observed in Hut78 than in Jurkat cell line.
Conclusions: High CCR7 expression in T-NHL cells is significantly associated with lymphatic and distant
dissemination as well as with tumor cell migration and invasion in vitro. Its underlying mechanism probably
involves the PI3K/Akt signal pathway.
Background
Currently, tumor growth and metastatic dissemination
result from a complex, dysregulated molecular machin-
ery, leading to resistance of tumor cells to apoptosis,
tumor cell migration, tumor cell invasion, and tumor
cell immune escape mechanisms. Recent data suggest
that chemokine receptors may direct lymphatic and
hematogenous spread, and may additionally influence
the sites of metastatic growth of different tumors[1].
Chemokine receptors are GTP-proteins linked to 7
transmembrane domains and they are expressed on the
cell membranes of immune and endothelial cells. CCR7,
the receptor for chemokine CCL21, was first discovered
on B cells infected by Epstein-Barr virus [2]. It is often
expressed on naive T cells, memory T cells, B cells, and
mature dendritic cells [3,4]. CCR7 is important for lym-
phatic cell migration and chemotaxis to lymph nodes.
CCR7 has two ligands, CCL19 and CCL21. CCL21 and
CCR7 are very important for T cell migration, activation,
and existence, especially for lymphocytic chemotaxis.
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sion. Patients often visit doctors when they develop mul-
tiple disseminated tumor sites. Normal T cells express
CCR7, and when cancer occurs, we have been unable to
determine if chemokine receptor expression increase
and whether it promoted tumor growth and dissemina-
tion. The role of chemokine receptors in tumor spread-
ing has been the focus of recent studies. High CCR7
expression has been associated with lymph node metas-
tases and poor prognosis in oral squamous cell carci-
noma and melanoma [5,6]. Supporting data from in
vitro and murine tumor models underline the key roles
of two receptors, CCR7 and CXCR4 in tumor cell
malignancy. Stimulation of CCR7 by its ligand CCL21
induces migration and invasion of CCR7-expressing can-
cer cells [7]. Furthermore, inhibition of the chemokine
receptors, such as CXCR4 and SDF-1, could suppress
chemokine-induced migration, invasion, and angiogen-
esis [8,9]. However, no studies have been done on CCR7
expression in human T-NHL and its effects on disease
progression and prognosis. Therefore, we evaluated
CCR7 expression in T-NHL cell lines and specimens,
and analyzed its correlation with clinicopathologic para-
meters of patients. Our results reveal that high CCR7
expression significantly influences lymphatic and hema-
togenous tumor dissemination, and also correlates with
clinical staging. Moreover, we investigated the underly-
ing mechanisms. We found that high CCR7 expression
is associated with lymphatic and distant dissemination
in patients with T-NHL, probably via the PI3K/Akt sig-
nal pathway.
Methods
Clinical Data
Materials
We collected 41 specimens of T-cell non-Hodgkin’s
lymphoma and 19 lymph nodes of reactive hyperplasia
from 2003 to 2008 in the General Hospital of Tianjin
Medical University. All specimens were formalin-fixed
and embedded in paraffin. Not all patients underwent
treatment on their visits. Of the 41 T-NHL patients, 23
were males and 18 were females. The mean age was
48.34 ± 16.19 years. According to the WHO classifica-
tion, the histological types of the specimens in our study
included peripheral T cell lymphoma, not otherwise
characterized (32 cases), extranodal NK/T cell lym-
phoma, nasal type (5 cases), anaplastic large cell lym-
phoma (2 cases), and angioimmunoblastic T cell
lymphoma (2 cases).
Method
Immunohistochemical Staining The avidin-biotin com-
plex method was used to detect the CCR7 (anti-CCR7,
1:300 dilution; Epitomics Inc.), MMP-2 (anti-MMP-2,
1:250 dilution; Zhong Shan Inc., Beijing), and MMP-9
(anti-MMP-9, 1:250 dilution; Zhong Shan Inc., Beijing).
The formalin-fixed, paraffin-embedded tissues were
deparaffinized and subsequently heated in a microwave
oven with EDTA buffer. After preincubation with hydro-
gen peroxide, an avidin/biotin blocking kit, and rabbit
serum, the primary antibodies were applied overnight in
the wet box at 4°C, and then incubated with the second-
ary antibodies (rabbit anti-goat biotinylated; 1:200 dilu-
tion, ZhongShan Inc., Beijing) for about 50min. At last
avidin-biotin complex was added, and enzyme activity
was visualized with diaminobenzidine. Counterstaining
was done with hematoxylin. For the negative controls,
only the secondary antibodies were used. A negative
control was done for every lymphoma and reactive
lymph node sample (n = 60). For the positive controls,
formalin-fixed, paraffin-embedded tissue samples of the
human spleen were applied.
Evaluation of Immunohistochemical Staining Immu-
nohistochemical staining was independently evaluated
by four authors, blinded to patient outcome and all clin-
icopathologic findings. The immunohistochemical stain-
ing was analyzed according to staining index, which was
calculated by multiplying the score for staining intensity
(0, absent, no color in tumor cells; 1, weak, pale yellow
in tumor cells; 2, intermediate, yellow in tumor cells; 3,
strong staining, brown yellow in tumor cells) with the
score for percentage of stained tumor cells (0, positive
cells account for 0%-10%; 1, 11%-25%; 2, 26%-50%; 3,
>50%). The staining index value ranges from 0 to 9. The
specimens grouped by staining index value as - (<2), +
(2-4), ++ (5-7), +++ (8-9). The slide of ++ or higher
than ++ was classified as high expression. Otherwise,
the slide was classified as low expression. The slides
were usually evaluated by four observers. The final clas-
sification of a slide was determined by the value agreed
to by a majority of observers.
In vitro Experimentation
Materials
Cell Culture The human cutaneous T cell lymphoma
cell line Hut78 and the adult T lymphocytic leukemia/
lymphoma Jurkat cell line were inoculated into cellular
culture boards with improved 1640 medium supplemen-
ted with 10% fetal bovine serum (Hyclone, Inc., USA),
100 units/mL penicillin, 100 μg/mL streptomycin (Cam-
brex, East Rutherford, NJ), and 1 mmol/L L-glutamine.
CCL21 were mixed into media to final concentrations of
50 (S50 group), 100 (S100 group), and 200 nmol/L (S200
group). Two cell lines were aggregated and grown in the
same suspension.
Method
RNA Isolation and Semiquantitative Reverse Tran-
scriptase Polymerase Chain Reaction (RT-PCR) RNA
isolation was done using the RNeasy Kit according to
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American). Gene transcriptions of actin, CCR7, PI3K,
and Akt were analyzed via a two-step RT-PCR. Reverse
transcription was done with 2 μgo fR N A( 2 0μLt o t a l
volume; Omniscript RT Kit, Qiagen) according to the
manufacturer’s recommendations. Up to 1 μLo fc D N A
was used as a template for the specific PCR reactions.
The primers used were as follows: b-actin, forward 5’-
CCTGGGCATGGAGTCCTGTG-3’ and reverse 5’-
AGGGGCCGGACTCGTCATAC-3’ (305 bp fragment);
CCR7, forward 5’-TCCTTCTCATCAGCAAGCTGTC-3’
and reverse 5’-GAGGCAGCCCAGGTCCTTGAA-3’ (529
bp fragment); PI3K, forward 5’-CATCACTTCC
TCCTGCTCTAT-3’ and reverse 5’-CAGTTGTTGG-
CAATCTTCTTC-3’ (377 bp fragment); Akt, forward 5’-
GGACAACCGCCATCCAGACT-3’ and reverse 5’-
GCCAGGGACACCTCCATCTC-3’ (121 bp fragment).
For amplification, a DNA Engine PTC200 (MJ Research,
Watertown, MA) thermocycler was used. The cycling
conditions for the respective PCRs were as follows:
initial denaturation (10 min at 95 °C) followed by 35
cycles of denaturation (30 s at 94 °C), annealing (30 s at
the following temperatures: b-actin, 59 °C; CCR7, 53 °C;
PI3K, 53 °C; Akt, 56 °C), and elongation (1 min at 72 °
C). After the last cycle, a final extension (10 min at 72 °
C) was added and, thereafter, the samples were kept at
4° C .T h e n ,5μL of the products were run on a 1%
agarose gel under a constant voltage of 100 V for 20
min, stained with ethidium bromide, and then analyzed
it under UV light.
Western Blot Analysis Hut 78 and Jurkat cells were
washed in PBS and lysed in RIPA lysate solution (Solar-
b i oI n c . ) .T h e n ,1 0 0μg of protein were separated by
10% SDS-PAGE. After separation, the protein were
transferred from the gel onto a polyvinylidene difluoride
membrane. The respective proteins were detected by
anti-CCR7 (1:3000, Epitomics Inc., 1:1000 rabbit anti-
goat IgG second antibodies, Zhongshan Inc., Beijing),
anti-Akt (1:1000, Beyotime Inc., Shanghai, 1:1000 rabbit
anti-goat IgG second antibodies, Zhongshan Inc., Beij-
ing), anti-p-Akt (1:2000, Epitomics Inc., 1:1000 rabbit
anti-goat IgG second antibody, Zhongshan Inc., Beijing),
and anti-GAPDH (1:1000, Santa Cruz, America; 1:1000
goat anti-rabbit IgG second antibodies, ZhongShan Inc.,
Beijing), and were visualized with an ECL Western blot-
ting analysis system.
Cellular Invasion Assays Invasiveness assays of Hut 78
and Jurkat cells were performed in a Transwell chamber.
(8 μm pore size; Corning Inc.). Each group of cells was
centrifuged and washed in PBS, resuspended with super-
natant, and adjusted to a cellular density of 5 × 10
5.
Then, 100 μL of the cell suspension from each group
was placed into the upper Transwell chambers and 600
μL of culture fluid with the corresponding CCL21
concentration was placed into the lower chamber. The
chambers were then incubated for 24 hours at 37 °C in
a humid atmosphere of 5% CO2. After incubation, the
number of cells that migrated to the lower chamber was
determined with eosin staining. The cells entered the
substrate in the lower chamber and then were mixed
uniformly. At last, we counted the cells under the
microscope (10 randomly selected high power fields)
individually.
Statistical Analysis
Data were analyzed with SPSS 11.5 software. Statistics
processing about clinical data were evaluated with c
2
test, Spearman’s rank correlation test. Statistics proces-
sing about in vitro experimentation were t test and
ANOVA. P < 0.05 was considered significant and P <
0.001 highly significant in all statistical analyses.
Results
Immunohistochemical Staining of CCR7, MMP-9, and
MMP-2 (Table 1)
The result for CCR7, MMP-9, and MMP-2 revealed a
predominantly cytoplasmic staining. A focal weak mem-
brane staining (Figure 1) was observed. The high expres-
sion ratio of CCR7, MMP-9, and MMP-2 were 82.9%,
87.8%, and 70.7% in T-NHL specimens, respectively. All
markers’ high expression ratios were higher than that in
hyperplastic lymph node group (P < 0.01).
Expression of all parameters in T-NHL group and
correlation with clinical parameters
(1) There was no significant correlation of high CCR7
expression ratio with age (87.5% >60 years vs 81.8% <=60
years), sex (87% males vs. 77.8% females) and tumor size
(88.0% >3 cm vs. 75.0% <3 cm) (Table 2). The positive
correlation between high CCR7 expression and multiple
location dissemination was found. The CCR7 expression
ratio of the multiple locations group was higher than that
in the single location group (92.6% vs. 64.3%, P < 0.05).
Concerning WHO classification, the high expression
ratio of CCR7 also was highly significantly associated
with higher tumor UIUC stages. UICC stage III and IV
group had 100% high CCR7 expression compared with
75% in UICC stage I and II group(P < 0.05).
Table 1 The chemokine receptor expression ratios of T-
NHL group and comparison group [number of cases (%)]
Group n CCR7 MMP-9 MMP-2
T-NHL group 41 34 (82.9) 36 (87.8) 29 (70.7)
Control group 19 3 (15.8) 3 (15.8) 2 (10.5)
c
2 32.219* 29.598* 18.845*
*P < 0.01
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tions group (96.3%) was higher than that in the single
location group (71.4%), in the clinical stage III-IV group
(100%) than that in the clinical stage I-II group (79.2%),
and in the >3 cm tumor size group that in the ≤3c m
group (96% vs. 75%, P < 0.05). MMP-9 expression ratio
showed no signification difference in gender and age.
The highly positive correlations of MMP-9 expression
ratio with multiple location dissemination, higher UICC
stages and larger tumor size were observed. (Table 2);
(3) Contrary to CCR7 and MMP-9, MMP-2 showed
higher expression in single location group compared
with multiple locations group (52.9% vs. 83.3%, P <
0.05). MMP-2 expression was also significantly asso-
ciated with lower UIUC stages (83.3% vs 52.9%).
(4) Other clinical parameters without statistical signifi-
cance were not included in the table.
Correlation among all indices in T-NHL
The high expression of CCR7, MMP-9, and MMP-2 in
T-NHL was analyzed with Spearman’s correlation analy-
sis. The relationship between CCR7 and MMP-9 (rs =
0.395, P < 0.05) expressed direct correlation. The rela-
tionship among other markers showed no significant
correlation (P > 0.05).
Figure 1 The expression of CCR7, MMP-9 and MMP-2 in T-NHL with immunohistochemical staining. These markers all express in the
cytoplasm. Some yellow or brown yellow granules in the cytoplasm are postive. The immunohistochemical staining was performed with S-P
method and these photoes were taken under the high power (×400). A was CCR7 stainting. The staining intensity is strong. B was MMP-9
stainting. The staining intensity is strong. C was MMP-2 staining. The staining intensity is intermediate.
Table 2 The correlation between clinical parameters and
higher expression of the three pathological parameters
[number of cases (%)]
Clinical-Pathology n CCR7 MMP-9 MMP-2
Sex
Male 23 20 (87.0) 20 (87.0) 18 (78.3)
Female 18 14 (77.8) 16 (88.9) 11 (61.1)
Age
≤60 years 33 27 (81.8) 29 (87.9) 25 (75.8)
>60 years 8 7 (87.5) 7 (87.9) 4 (50)
Tumor size
≤3 cm 16 12 (75.0) 12 (75.0) * 13 (81.3)
>3 cm 25 22 (88.0) 24 (96.0) * 16 (64)
Clinical Stage
Stage I-II 24 18 (75.0) * 19 (79.2) * 20 (83.3) *
Stage III-IV 17 17 (100.0) * 17 (100.0) * 9 (52.9) *
B symptom
No 16 13 (81.3) 13 (81.3) 11 (68.8)
Yes 25 21 (84.0) 23 (92.0) 18 (72)
Location
Single location 14 9 (64.3) * 10 (71.4) * 12 (85.7) *
Multiple location 27 25 (92.6) * 26 (96.3) * 17 (63) *
* P < 0.05
Table 3 Cellular count in the lower chamber in Transwell
invasion experiment (¯ x ±s ,n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 10.63 ± 5.52 20.70 ± 8.40
✩ 33.43 ±
10.61
✩
49.13 ±
21.01
✩
Hut
78
15.00 ± 6.48
⋆ 35.37 ±
18.21
⋆▴
42.26 ±
20.17
▴
72.60 ±
34.12
⋆▵
⋆Compared with corresponding group of Jurkat cells, P < 0.01;
✩Compared with the other groups of Jurkat cells (including the control
group), P < 0.01;
▴Compared with the control group and of S200 group of Hut 78 cells, P < 0.01;
▵Compared with the other groups of Hut 78 cells (including the control
group), P < 0.01.
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In the lower chamber, there were more Hut 78 cells than
Jurkat cells in all groups except S100 group (P < 0.01).
The number of Hut 78 and Jurkat cells that pene-
trated the membrane in the S50,S 100,a n dS 200 groups
were all higher than that in the control group (P < 0.01).
For the Hut 78 cell line, the cells in the S200 group
were higher than that in the S50 group, whereas for the
Jurkat cell line, the cells in the S100 group were higher
than that in S50 group, and the cells in S200 were higher
than that in S100 group (P < 0.01).
The expression and transcript of CCR7 in two cell lines
under conventional culture and CCL21 co-culture
(1) CCR7mRNA transcript (Table 4, Figure 2)
According to the relative grey scale, the numbers of CCR7
transcripts of the two cell lines in all concentration groups
were higher than that in the control group (P < 0.01).
The CCR7 transcripts of the Hut 78 cells in control,
S50, and S100 groups were higher than that in the corre-
sponding groups of Jurkat cells (P < 0.01).
The CCR7 transcripts of the two cell lines in the
higher concentration group were higher than that in the
lower concentration group, except for S100 and S200
groups in the Hut 78 cell line (P < 0.01).
(2) Expression of CCR7 protein (Table 5, Figure 2)
In both cell lines, the relative expression of the CCR7 pro-
tein in the S100 and S200 groups were higher than that in
the control group, whereas the CCR7 expression in the S100
group was higher than that in the S50 group (P <0 . 0 1 ) .
T h eC C R 7e x p r e s s i o no ft h eH u t7 8c e l ll i n ei nt h e
control, S50,S 100,a n dS 200 groups were higher than
those of the Jurkat cell line (P < 0.01).
The expression and activation of PI3K/Akt pathway in the
two cell lines under conventional culture and CCL21 co-
culture
(1) PI3K mRNA transcript (Table 6, Figure 3)
The relative PI3K mRNA expression levels in all concen-
tration groups were higher than that in the control
group (P < 0.01). The relative PI3Km R N Ae x p r e s s i o n
levels of the Jurkat cells in the S100 and S200 groups
were both higher than that in the S50 group. The
expression in the S200 group was lower than that in the
S100 group (P < 0.05). For the Hut 78 cells, there were
no significant differences in relative expression levels in
all three concentration groups. The relative expression
levels in the control and S200 groups were both higher
than that in the Jurkat cells. The relative expression
levels had no significant differences between Hut 78 and
Jurkat cells in S50 and S100 groups.
(2) Akt mRNA transcript (Table 7, Figure 4)
The relative Akt mRNA expression levels in all concen-
tration groups were higher than that in the control
group (P < 0.01). The relative Akt mRNA expression
levels of the Hut 78 cells in the control, S50,S 100,a n d
S200 groups were all higher than those of the Jurkat cells
(P < 0.05). The relative expression levels of the two cell
Table 4 The relative grey scale of CCR7mRNA transcript
(¯ x ±s ,n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 0.1512 ±
0.0278
0.4604 ±
0.0331
✩
0.7453 ±
0.0636
✩
0.9071 ±
0.4985
✩
Hut
78
0.5282 ±
0.0537
⋆
0.6943 ±
0.0365
⋆▵
0.8477 ±
0.0513
⋆▴
0.8710 ±
0.0485
▴
⋆Compared with the corresponding group of Jurkat cells, P < 0.01;
✩Compared with the other groups of Jurkat cells (including the control
group), P < 0.01;
▴Compared with the control group and S50 group of Hut 78 cells, P < 0.01;
▵Compared with the other groups of Hut 78 cells (including the control
group), P < 0.01.
Figure 2 The expression of CCR7 mRNA and protein in Jurkat
and Hut cells after CCL21 co-culture in vitro. RT-PCR amplication
and Western Blot analysis of the two cell lines under the different
concentration of CCL21, which was performed as described in
Methods. b-actin is positive control in RT-PCR amplication and
GAPDH is positive control in Western Blot analysis. The relative grey
scale of CCR7 mRNA and protein in Hut cell were both higher than
that in Jurkat cell with corresponding concentration of CCL21. In
the group with different concentration of CCL21 of each cell lines,
there were some differences on the grey scale as described in the
result.
Table 5 The relative grey scale of CCR7 protein (¯ x ±s ,
n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 0.5053 ±
0.0336
0.4870 ±
0.0278
0.6916 ±
0.0238
✩
0.7095 ±
0.0332
✩
Hut
78
1.1037 ±
0.1135
⋆
1.0700 ±
0.1121
⋆
1.4792 ±
0.2500
⋆▴
1.4804 ±
0.2524
⋆▴
⋆Compared with the corresponding group of Jurkat cells, P < 0.01;
✩Compared with the control group and the S50 group of Jurkat cells, P < 0.01;
▴Compared with the control group and the S50 group of Hut 78 cells, P <
0.01.
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cantly higher than that in lower concentration group
(Table 7).
(3) p-Akt protein expression (Table 8, Figure 4)
For the Hut 78 cells, the relative p-Akt protein expres-
sion levels in all concentration groups were all signifi-
cantly higher than that in control group. The expression
in the S100 group was significantly higher than those in
the S50 and S200 groups.
For the Jurkat cells, the relative p-Akt protein expres-
sion levels of in the S100 and S200 groups were signifi-
cantly higher than that in the control group and the
expression in the higher concentration group was signif-
icantly higher than that in the lower concentration
group.
The relative expression levels of Hut 78 cells in the
control, S50,S 100,a n dS 200 groups were higher than
those of Jurkat cells.
Discussion
This is the first study analyzing the expression profiles
of CCR7 chemokine receptors in a larger series of
human T cell lymphoma tissues and cell lines. We
further determined whether CCR7 expression influenced
tumor cell migration in vitro and the metastatic
behavior of T-NHL and its prognosis in patients, as
recently reported for many other malignant tumors. In
2001, Müller [10] first reported breast carcinoma with
higher expression of a CCR7 chemokine receptor in pri-
mary and metastatic foci. He also found high expression
of CCL21 in metastatic sites, such as lymph node, lung,
liver, and bone marrow. In an in vitro experiment, he
found that SDF-1 increased F actin expression in the
tumor cells, which can form pseudopodia. In addition,
CCL21 also induced breast carcinoma cell migration
and basement membrane invasion. CCR7 expression has
previously been associated with intrapleural dissemina-
tion in non-small cell lung cancer [11], gastric carci-
noma [12], and so on, implying the relevant function of
CCR7 expressing during carcinogenesis in these cancers.
The theory of a CCR7-co-mediated mechanism of lym-
phatic dissemination was also supported by an animal
study, revealing that the CCR7 expression of melanoma
cells increases metastases formation in the regional
lymph nodes of mice [13]. Moreover, using monoclonal
Table 6 The relative grey scale of PI3KmRNA (¯ x ±s ,n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 0.2170 ±
0.0289
0.7897 ±
0.0549
✩
0.8310 ±
0.0377
✩▵
0.8248 ±
0.0381
▵
Hut
78
0.6061 ±
0.0545
#
0.7996 ±
0.0200
▴
0.8365 ±
0.0346
▴
0.8759 ±
0.0467
⋆▴*
⋆Compared with the corresponding group of Jurkat cells, P < 0.05;
# Compared with the corresponding group of Jurkat cells, P < 0.01;
✩Compared with the control group of the Jurkat cells, P < 0.01;
▵Compared with the other groups of Jurkat cells, including the control group,
P < 0.05;
▴Compared with the control group of Hut 78 cells, P < 0.01;
* Compared with the S50 group of Hut 78 cells, P < 0.01.
Figure 3 The expression of PI3K mRNA in Jurkat and Hut cells
after CCL21 co-culture in vitro. RT-PCR amplication of the two
cell lines under the different concentration of CCL21. The relative
grey scale of PI3K mRNA in Hut cell was higher than that in Jurkat
cell with corresponding concentration of CCL21. there were some
difference on the grey scale in the group with different
concentration of CCL21 of each cell lines. b-actin is positive control
in RT-PCR amplication.
Table 7 The relative grey scale of the Akt mRNA (¯ x ±s ,
n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 0.1808 ±
0.0264
0.3224 ±
0.0172
✩
0.5194 ±
0.0340
✩
0.6305 ±
0.0212
✩
Hut
78
0.2279 ±
0.0183
⋆
0.6418 ±
0.0344
⋆▵
0.7107 ±
0.0149
⋆▵
0.7325 ±
0.0234
⋆▵
⋆Compared with the corresponding group of Jurkat cells, P < 0.01;
✩Compared with the other groups of Jurkat cells, including the control group,
P < 0.01;
▵Compared with the other groups of Hut 78 cells, including the control group,
P < 0.05.
Figure 4 The expression of Akt mRNA, Akt protein and p-Akt
protein in Jurkat and Hut cells after CCL21 co-culture in vitro.
RT-PCR amplication and Western Blot analysis of the two cell lines
under the different concentration of CCL21. b-actin is positive
control in RT-PCR amplication and GAPDH is positive control in
Western Blot analysis. The relative grey scale of Akt mRNA, Akt
protein and p-Akt protein in Hut cell were all higher than that in
Jurkat cell with corresponding concentration of CCL21.
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metastasis. CCR7-mediated lymphatic dissemination had
been compared with the chemotaxis of activated dendri-
tic cells to CCL21-expressing lymph nodes via lymphatic
vessels [7,12,14-16].
Diverse functional studies investigating the influence of
CCR7 expression and the activation by its ligand CCL21
were recently conducted, revealing that CCR7 is crucial
for adhesion, migration, and invasion of CCR7-expressing
malignant tumors [11-13]. To confirm the function of
CCR7 in T-NHL, we performed migration and invasion
assays using Hut 78 and Jurkat cells. In the vitro experi-
ment, we found that the invasiveness of Hut 78 cell
through a Transwell chamber was higher than that of
Jurkat cells. Moreover, the CCR7 mRNA transcript and
protein expression of Hut 78 cells were also higher than
that of Jurkat cells. The migration of these two CCR7
expressing cell lines was significantly stimulated by
CCL21, implying an important role and intact function
of CCR7 during tumor progression. The invasion capabil-
ity of these two cell lines is associated with the CCL21
concentration gradient. However, CCR7 protein expres-
sion was no significant difference between S100 group
and S200 group. CCR7 expression in S200 group was even
lower than that in S100 group. Therefore, the ideal CCL21
concentration for CCR7 expression in T cell lymphoma is
50-100 nmol/L. This result is consistent to that in the
experiment by Mafei [17]. They proposed that the ideal
CCL21 concentration for CCR7 expression in breast car-
cinoma is 50-500 nmol/L. Under this CCL21 concentra-
tion, CCR7 can achieve maximum expression in
regulating neoplastic cell chemotaxis and invasion. The
concentrations beyond 50-500 nmol/L could affect CCR7
expression and subsequently influence chemotaxis and
invasiveness. These results indicate that the intensity of
CCL21-induced cell migration and invasion in vivo corre-
lates with cellular CCR7 expression.
Previous publications have reported that CCR7 activa-
tion is critical for metastasis to lymph nodes, lungs, and
liver. The mechanism is similar to that of lymphocytic
chemotaxis. One study reported that T-cell acute lym-
phoblastic leukemia is at an increased risk of central
nervous system (CNS) relapse. They identified a single
chemokine-receptor (CCR7 and CCL19) interaction as a
CNS “entry signal” [18]. CCL21 is mainly distributed
among peripheral immune organs, especially lymph
nodes and spleen. Gunn’s study showed that CCL21
could be found in the high endothelial vein of lymph
nodes and Peyer’s patches, T lymphatic zones, lymphoid
follicles, and endothelial cells of lymphatic vessel in
many organs. CCL21 can drive lymphocytes in human T
cell line and peripheral blood, but not chemotaxis for
neutrophils and monocytes, which suggest that CCL21
is specific for the trafficking of T lymphocytes [16].
CCL21 has dual effects on malignant tumor formation.
CCL21 can attract immune cells and inhibit vasculariza-
tion, which block tumor growth. Meanwhile, the
increase of CCR7 chemokine receptor expression pro-
motes tumor growth and metastasis. When the latter
effect is prominent, the tumor disseminates. Under nor-
mal conditions, CCR7 is expressed on T cells. When
malignancy occurs, the neoplastic T cell may enhance
the expression of CCR7. The differential expression of
CCL21 by endothelial cells might explain at least one
part of this process. Our results support the chemotaxis
theory that CCL21 expression co-mediates the dissemi-
nation of primary tumors to different organs [19]. Hase-
gawa [20] found that adult T cell leukemia/lymphoma
(ATLL) cells with high CCR7 expression have increased
directional migration capability toward CCL21, which
suggests that CCR7 expression may facilitate ATLL cell
movement to the high endothelial vein of lymph nodes
with abundant CCL21, and then to metastasis.
The influence of CCL21 on lymphatic dissemination
(compared with hematogenous) has not been investi-
gated thus far, but CCL21 is also highly expressed in
lymph nodes, and CCR7 inhibition results in suppres-
sion of breast cancer lymph node metastases, which
implies similar pathways for lymphatic and hematogen-
ous dissemination [10].
PI3K/Akt, an intracellular signal pathway, plays a role
in the invasion of many malignant tumors. Whether
PI3K/Akt participates in the invasion and metastasis of
T cell lymphomas induced by CCR7 and if a relation-
ship exists between them remains unclear.
The PI3K/Akt signal pathway was first found in the
1990’s. The catalysate of PI3K can participate in cellular
proliferation, living, differentiation, and migration [21].
Receptor protein tyrosine kinase (RPTK) activation
results in PI(3,4,5)P(3) and PI(3,4)P(2) production by
PI3K at the inner side of the plasma membrane. Akt
interacts with these phospholipids, causing its transloca-
tion to the inner membrane, where it is phosphorylated
Table 8 The relative grey scale of p-Akt protein after co-
culture (¯ x ±s ,n=9 )
Control
group
S50 group S100 group S200 group
Jurkat 0.5523 ±
0.0112
0.5680 ±
0.0566
▵
0.7784 ±
0.0694
✩
0.9184 ±
0.0668
✩
Hut
78
0.9171 ±
0.0483
⋆
1.1717 ±
0.1679
⋆*
1.3055 ±
0.0799
⋆▴
1.1507 ±
0.1010
⋆*
⋆Compared with the corresponding group of Jurkat cells, P < 0.01;
✩Compared with the other groups of Jurkat cells, including the control group,
P < 0.01;
▵Compared with the S100and the S200 groups of Jurkat cells, P < 0.01;
▴Compared with the other groups of Hut 78 cells, including the control group,
P < 0.01;
* Compared with the control and the S100 groups of Hut 78 cells, P < 0.01.
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modulates the function of numerous substrates which
are involved in the regulation of cell survival, cell cycle
progression, and cellular growth.
Several studies have proven that Akt expression is
excessively upregulated in many malignant tumors, such
as thyroid carcinomas, gliomas, breast carcinomas, pul-
monary carcinomas, and so on [22-26]. As a protein
kinase, Akt is activated through phosphorylation. The
upregulation of Akt protein may promote oncogenesis
and tumor growth. The expression level of phosphory-
lated-Akt is the indicator of the kinase activity.
In our experiment, the expression levels of PI3K
mRNA, Akt mRNA, and p-Akt protein in Hut 78 cells
were higher than that in Jurkat cells. The Hut 78 cells
were more invasive than the Jurkat cells. The invasive-
ness of T-NHL is associated with the CCR7 expression.
CCR7 is a transmembrane receptor of GTP-protein.
CCR7 may activate Akt and the PI3K/Akt signal path-
way to promote cell proliferation and spread. Noelia
[27] reported that CCR7 could activate the intracellular
PI3K/Akt signal pathway to promote cell proliferation
and suppress apoptosis in DC cells.
We have a hypothesis about how do CCR7 trigger
PI3K/Akt signal pathway. The expression of lymph node
chemokine in T-NHL could cause the upregulation of
chemokine receptors. The interaction between chemo-
kines and their receptors may then activate the Akt pro-
tein by peroxodiphosphoric acid, followed by the
activation of the PI3K/Akt signal pathway, which can
promote tumor cell proliferation and invasion. This
result provides a theoretical foundation for the targeting
of CCR7 and the PI3K/Akt signal pathway with antibo-
dies for the treatment of T-NHL. However, further stu-
dies on the concrete mechanism of activation of this
pathway and its downstream genes are still needed.
In this study, we also detected expression of MMP-9
and MMP-2. MMP is a matrix metalloproteinase that
breaks down and destroy Type IV and Type V collagen,
as well as gelatin in the extracellular matrix, and then
promote tumor metastasis. CCR7 expression in T-NHL
was directly correlated with MMP9 expression. High
MMP-9 expression has previously been reported in non-
Hodgkin’s lymphoma [28,29], which can influence the
biological behavior and clinical progression of tumor.
For T-NHL, a report in an animal experiment found
that the high expression of MMP-9 is correlated with
liver metastasis [30]. The high expression of MMP-9 is
also associated with bad prognosis. The relationship
between CCR7 and MMP-9 suggests that these two fac-
tors may enhance each other and promote tumor disse-
mination synergistically. However, the function of
MMP-2 in T-NHL metastasis is still unclear.
Conclusions
Higher CCR7 expression in T-NHL cells is significantly
associated with lymphatic and distant dissemination in
patients, as well as with migratory and invasive pheno-
types in vitro. Our study suggested that CCR7 plays an
important role in the progression of T-NHL. The possi-
ble mechanism is via the PI3K/Akt signal pathway.
Further studies are needed to evaluate the inhibition of
metastatic growth through blocking CCR7 and PI3K/Akt
signal pathway.
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